Hot Integrated Utility Stocks To Own For 2015

Hot Integrated Utility Stocks To Own For 2015: PDL BioPharma Inc.(PDLI)

PDL BioPharma, Inc. engages in intellectual property asset management and royalty bearing assets investment activities. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. patents that cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Advisors' Opinion:

• [By John Reese]

  Indeed, in 2013, the Greenblatt-based portfolio has bounced back strong, returning more than 50%. Below is a look at its current holdings.

  EBIX, Inc. (EBIX)
  
  Western Refining (WNR)
  
  DirecTV (DTV)
  
  ITT Educational Services (ESI)
  
  Science Applications International (SAIC)
  
  Weight Watchers International (WTW)
  
  ConocoPhillips (COP)
  
  AmSurg Corp. (AMSG)
  
  PDL BioPharma (PDLI)
  
  AFC Enterprises (AFCE)
  
  

  Subscribe to Validea here

• [By Matthew Indyke and Brian Zen]

  Four of Klarmans stocks include PDLBioPharma (PDLI), Ituran Location and Control (ITRN), BP (BP), and Microsoft (MSFT). What these companies have in common are annually increasing total revenues, annually increasing cash flows, and gradually decreasing operating expenses and debt. Additionally, they show a clear value focus with P/E ratios no greater than 15. And even when stocks like these go through a troubling period brought on by a sagging economy or major scandal, they have an ability to bounce back.

• [By Eric Volkman]

  PDL BioPharma (NASDAQ: PDLI  ) is ex! pecting a healthy bump in its royalty revenue for the current quarter, which ends on June 30. The company has issued guidance for the period, estimating that it will take in royalty revenue of around $143 million. That would represent a 13% increase over the Q2 2012 figure of $126 million.

• [By Selena Maranjian]

  PDL BioPharma (NASDAQ: PDLI  ) gained 28%, collecting royalties from a slew of medications. Its dividend yield was recently a hefty 7.6%, but investors are right to worry about its sustainability, since many of the company's revenue streams will dry up in coming years, as patents expire. Management has been seeking other revenue-generating assets and may find a new business strategy in making loans to other medical companies.

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/hot-integrated-utility-stocks-to-own-for-2015-2.html